Both Undertreatment and Overtreatment Common in JIA

New study evaluates disease activity in juvenile idiopathic arthritis

Many children with juvenile idiopathic arthritis have persistent disease activity a year after first presenting with symptoms.

Established targets for treatment in juvenile idiopathic arthritis cannot be compared directly if they use different outcome criteria.

Kimme L. Hyrich, MD, PhD, of the University of Manchester in the United Kingdom, and colleagues point out that because of the lack of consensus in diagnostic criteria, "the same child could be classified as 'in clinically inactive disease' or having active disease at the same time point between clinicians or hospitals."

Juvenile idiopathic arthritis is the single most common rheumatic disease affecting children. It is very challenging to define clinically inactive disease and/or minimal disease activity since there is no diagnostic test for either and much variability exists in proposed diagnostic criteria.

The authors see developing consistent criteria for clinically inactive disease and minimal disease activity and the standardization of outcome measures as crucial in establishing a valid target to treat children with idiopathic arthritis. They present their findings in a recent Annals of the Rheumatic Diseasesarticle.

"These differences highlight that the same child could be classified as 'in CID' or having active disease at the same time point between clinicians or hospitals. Future work needs to explore which treatment target predicts better long-term prognoses in JIA," the authors wrote.

"The current study highlights that even published targets intended to capture the same construct identify different groups of children. Results from studies using different outcome criteria therefore cannot be compared directly. In addition, if used as targets in clinical practice, using different targets may result in overtreatment or undertreatment."

The Study

A total of 1,415 children with juvenile idiopathic arthritis were included in this inception cohort study. The authors defined the outcomes as no active joint involvement and a score of zero on the physician or parental global evaluation survey.

Physicians' and parents' assessments were in concordance only 35% of the time with regards to a score of zero on the global assessments.

When the juvenile arthritis disease activity score and clinical juvenile arthritis disease activity score were compared, the authors found nearly 100% overlap, with both identifying 38% of children as in clinically inactive disease states at 1 year. Fewer children met clinically inactive disease criteria when Wallace's preliminary criteria were utilized (25%) with only 44% overlap between Wallace's and juvenile arthritis disease activity score groups.

Across all International League of Associations for Rheumatology subtypes outcome criteria were similar, with children achieving no active joints more often than minimal disease activity or clinically inactive disease on juvenile arthritis disease activity and Wallace's measures.

The variability of published targets of treatment in juvenile idiopathic arthritis makes it difficult to treat successfully.

The authors believe that, "using different targets in clinical practice may result in overtreatment or under treatment."

Current outcomes measures are falling short with broad achievement of clinically inactive disease and minimal disease activity reaching only 30% and 50%, respectively.

Current data support the use of the clinical juvenile arthritis disease activity score when assessing for clinically inactive disease.

This article originally appeared on our partner's website Rheumatology Network, which is a part of UBM Medica. (Free registration is required.)

The Medical Research Council, Arthritis Research UK, and National Institute for Health Research provided funding.

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.